Skip to main content
OpenTrials
Completed

NCT Number: NCT02956109

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a single oral dose of finerenone (1.25 mg tablet and 5 x 0.25 mg tablets) using a novel orodispersible tablet formulation for the treatment of children, in comparison to the adult tablet formulation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Mönchengladbach, North Rhine-Westphalia, 41061, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects
  • Age: 18 to 45 years (inclusive)
  • Body mass index (BMI) : ≥ 18 and ≤ 29.9 kg/m²
  • Race: White

Exclusion criteria

  • Subjects with conspicuous findings in medical history and pre-study examination in the opinion of the investigator
  • A history of relevant diseases of vital organs, of the central nervous system or other organs
  • Known renal or liver insufficiency
  • Subjects with diagnosed malignancy, psychiatric disorders, or thyroid disorders (evaluated by medical history, physical examination, clinical symptoms, and assessment of thyroid stimulating hormone at screening)
  • Medical disorder that would impair the subject's ability to complete the study in the opinion of the investigator
  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
  • Relevant diseases within the last 4 weeks prior to the first study drug administration
  • Smoking more than 10 cigarettes daily and/ or inability to refrain from smoking on the profile days until 8 h after administration
  • Vegetarian or special diets preventing the subjects from eating the standard meals during the study, especially the high-fat high-calorie American breakfast or reluctance to ingest it

Treatment and study plan

Finerenone (BAY94-8862): 1 0mg tablet

Drug

10 mg finerenone immediate-release tablet; single dose in the fasting condition

Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets

Drug

5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition

Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet

Drug

1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition

Primary outcomes

  1. Finerenone area under the plasma concentration vs. time curve (AUC)

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours

  2. Finerenone maximum plasma concentration (Cmax)

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours

  3. Appearance of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  4. Taste of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  5. Texture of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  6. Smell of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  7. Overall impression of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  8. Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

Secondary outcomes

  1. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: Up to 3 weeks

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Relative Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of Finerenone 1.25 mg and 5 x 0.25 mg Orodispersible Tablet (Pediatric Formulation) in Comparison to 10 mg Tablet (Adult Formulation) in the Fasting Condition and to Investigate the Effect of a High Fat, High Calorie Meal on 1.25 mg Oro-dispersible Tablet in Healthy Male Subjects in a Randomized, Open-label, Four-fold Crossover Design

Important dates

Study start
2016
Primary completion
2016
Study completion
2017
First posted
Nov 4, 2016
Registry last updated
Jul 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.